China NDA grants approval of Roche's Alecensa (alectinib) for ALK-positive NSCLC
Roche announced the CNDA has granted marketing authorisation for Alecensa® (alectinib) as a monotherapy treatment for patients with anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell lung cancer. The approval follows priority review of Alecensa in China.
August 20, 2018